Feed EXAS
EX

Exact Sciences

EXAS · NASDAQ

$104.91 +0.00% (+$0.00)
Market Cap $20.0B
P/E Ratio -
Div. Yield -
ROE 8.51%

Bulios Fair Price

$61.57

41.3% downside

Trenutna cena

$104.91

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica EXAS trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Analiza

AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.

Piotroski F-Score Moderate
5/9
Valuation
3 /100
Expensive
EV/EBITDA 506.73x
P/S 6.17x
P/B 8.34x
Growth
63 /100
Stable
Rev. growth 18.79%
FCF growth 23.79%
Book val. growth 12.05%
Profitability
41 /100
Moderate
Gross margin 69.69%
Net margin 6.40%
Op. margin 6.17%
Quality
7 /100
Poor
ROIC 3.89%
ROE 8.51%
ROA 3.55%
Debt
29 /100
High
Debt/Equity 1.05x
Current ratio 2.23x
Int. coverage -4.88x
Stability
58 /100
Moderate
Beta 1.44x
Rev. volatility 1.03%
EPS volatility 35.01%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o EXAS
Online

O podjetju

Exact Sciences Corporation (EXAS) is an American company that specializes in the development and commercial distribution of diagnostic tests for cancer prevention and detection. Their main product is Cologuard, a non-invasive stool test used for detecting colorectal cancer and advanced adenomas. This test allows patients to undergo cancer screening at home, providing significant advantages compared to traditional screening methods such as colonoscopies. In addition to this, Exact Sciences invests in research and development of new diagnostic tests for various types of cancer and other diseases. Exact Sciences Corporation (EXAS) shares may be attractive to investors seeking investments in companies operating in the cancer diagnostics field with an emphasis on innovation and improving healthcare.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

CEO

Kevin T. Conroy

Employees

6,900

Headquarters

Madison

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.